Abstract

BackgroundMalignant melanoma is an aggressive type of skin cancer, and despite recent advances in treatment, the survival rate of the metastatic form remains low. Nifuroxazide analogues are drugs based on the substitution of the nitrofuran group by benzofuroxan, in view of the pharmacophore similarity of the nitro group, improving bioavailability, with higher intrinsic activity and less toxicity. Benzofuroxan activity involves the intracellular production of free-radical species. In the present work, we evaluated the antitumor effects of different benzofuroxan derivatives in a murine melanoma model.MethodsB16F10-Nex2 melanoma cells were used to investigate the antitumor effects of Benzofuroxan derivatives in vitro and in a syngeneic melanoma model in C57Bl/6 mice. Cytotoxicity, morphological changes and reactive oxygen species (ROS) were assessed by a diphenyltetrasolium reagent, optical and fluorescence microscopy, respectively. Annexin-V binding and mitochondrial integrity were analyzed by flow cytometry. Western blotting and colorimetry identified cell signaling proteins.ResultsBenzofuroxan N-Br and N-I derivatives were active against murine and human tumor cell lines, exerting significant protection against metastatic melanoma in a syngeneic model. N-Br and N-I induce apoptosis in melanoma cells, evidenced by specific morphological changes, DNA condensation and degradation, and phosphatidylserine translocation in the plasma membrane. The intrinsic mitochondrial pathway in B16F10-Nex2 cells is suggested owing to reduced outer membrane potential in mitochondria, followed by caspase −9, −3 activation and cleavage of PARP. The cytotoxicity of N-Br and N-I in B16F10-Nex2 cells is mediated by the generation of ROS, inhibited by pre-incubation of the cells with N-acetylcysteine (NAC). The induction of ROS by N-Br and N-I resulted in the inhibition of AKT activation, an important molecule related to tumor cell survival, followed by upregulation of BIM.ConclusionWe conclude that N-Br and N-I are promising agents aiming at cancer treatment. They may be useful in melanoma therapy as inducers of intrinsic apoptosis and by exerting significant antitumor activity against metastatic melanoma, as presently shown in syngeneic mice.

Highlights

  • Malignant melanoma is an aggressive type of skin cancer, and despite recent advances in treatment, the survival rate of the metastatic form remains low

  • We explored the capacity of nifuroxazide analogues to induce reactive oxygen species (ROS)-mediated apoptosis in B16F10-Nex2 murine melanoma cells

  • In vitro and in vivo antitumor activity of benzofuroxan compounds The cytotoxicity of the compounds (Table 1) and the N-Br and N-I derivatives was investigated primarily on murine melanoma B16F10-Nex2 cells at 100 μM for 16 h

Read more

Summary

Introduction

Malignant melanoma is an aggressive type of skin cancer, and despite recent advances in treatment, the survival rate of the metastatic form remains low. 5-Nitrofurans being constituents of widely used medications, may cause toxic side effects such as polyneuropathy, depression, forgetfulness, alcohol intolerance, headaches as well as gastrointestinal complications, which interfere with their use [2] In this context, nifuroxazide analogues were developed replacing the nitrofuran group by benzofuroxan based on the pharmacophore similarity attributed to the nitro group, and to improve bioavailability, with higher intrinsic activity and less toxicity [2]. Melanoma is a deadly type of cancer that results from the malignant transformation and uncontrolled proliferation of melanocytes It is the most invasive skin cancer with increasing incidence and poor prognosis in the metastatic stage [5, 6]. Novel therapeutic approaches are still needed, especially for the metastatic form

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call